A live or inactivated recombinant vaccine is described, comprising a viral vector and a pharmaceutically acceptable vehicle, adjuvant and/or excipient, wherein the viral vector is capable of generating a cell immune response due to an increased alpha and/or gamma interferon production, and is capable of a quick replication, and it has inserted a nucleotide sequence of the ORF 5 and ORF 6 from PRSS.
